Prescribing of lipid regulating drugs and admissions for myocardial infarction in EnglandBMJ 2004; 329 doi: http://dx.doi.org/10.1136/bmj.329.7467.645 (Published 16 September 2004) Cite this as: BMJ 2004;329:645
- Azeem Majeed,
- Paul Aylin,
- Susan Williams,
- Alex Bottle,
- Brian Jarman
Despite declining death rates in recent decades, coronary heart disease remains one of the leading causes of death in England.w1 Statins have been shown to reduce the risk of death and acute myocardial infarction in people who have coronary heart disease or are at high risk of developing it.w2-w4 A key objective of the national service framework for coronary heart disease is to increase the uptake of statins in these two groups. We conducted an analysis of primary care prescribing of lipid regulating drugs and admission rates for acute myocardial infarction in the NHS for 1996-2002.
The bottom line
• Large increases in the cost and volume of prescribing of lipid regulating drugs have been associated with only a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial